Joseph Todisco is recorded as Chairman at CorMedix Inc. (CRMD) since January 8, 2026, Board Member at CorMedix Inc. (CRMD) since January 1, 2022 and CEO at CorMedix Inc. (CRMD). The newest filing on record that lists Joseph Todisco as CEO and Board Member at CorMedix Inc. (CRMD) is dated April 29, 2026. CorMedix Inc. reported in an 8-K filed January 8, 2026 that Joseph Todisco was appointed Chairman of the Company's board of directors, effective January 8, 2026. The proxy statement of CorMedix Inc. reports total compensation of $6,101,176 for Joseph Todisco in fiscal 2025, including a base salary of $684,353. Disclosed compensation is on record for 6 fiscal years. Joseph Todisco has spoken on 7 earnings calls across 1 company, most recently for CorMedix Inc. on May 14, 2026. CorMedix Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at CorMedix Inc. includes Matt David, M.D. (CEO), Robert W. Cook (CFO), Susan Blum (CFO) and 7 others.
“Mr. Todisco's appointment as Chairman of the Board, effective January 8, 2026, was approved by the Board on January 5, 2026.”
CorMedix Inc. Form 8-K, filed January 8, 2026
· Read the filing
Joseph Todisco on recent calls
“CorMedix is entering 2026 with strong momentum across our core priorities, delivering durable DefenCath utilization growth, advancing high-value pipeline opportunities and driving meaningful profitability and cash generation.”
“This has been an exciting quarter in the evolution of CorMedix as we announced and closed the acquisition of Melinta Therapeutics in a combination of cash and stock transaction.”
“Today, concurrent with our second quarter earnings announcement, CorMedix announced the acquisition of Melinta Therapeutics in a combination cash and stock transaction.”
“As we approach tomorrow's target action date for DefenCath, I am very pleased with the progress that the company has made toward pursuing final NDA approval from the FDA, as well as preparations for commercialization.”
